With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1067-33-0,Dibutyltin diacetate,as a common compound, the synthetic route is as follows.
[Example 7] 306 g of a residual liquid were obtained by carrying out the same method as Example 6 with the exception of using 255 g of di-n-butyl tin diacetate, and using 961 g of 3-methyl-1-butanol (Tokyo Chemical Industry Co., Ltd., Japan) instead of 2-ethyl-1-butanol. The residual liquid contained 92.7% by weight of di-n-butyl-bis(3-methylbutyloxy) tin. In addition, the low boiling point component contained 18.0% by weight of isoamyl acetate.
The synthetic route of 1067-33-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Asahi Kasei Chemicals Corporation; EP2226328; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI